The impact of chronic in vivo glucocorticoid excess on the functional characteristics of human skin fibroblasts obtained from patients with endogenous Cushing's syndrome.

The impact of chronic in vivo glucocorticoid excess on the functional characteristics of human skin fibroblasts obtained from patients with endogenous Cushing's syndrome.

OBJECTIVE: Chronic exposure to elevated glucocorticoid (GC) concentrations induces detrimental effects in several tissues. In the skin, GCs provoke intense alterations on various parameters of the physiology of fibroblasts, cumulatively leading to skin atrophy and impaired wound healing. As there a...

Descripció completa

Dades bibliogràfiques
Autors principals:	Zervolea, I, Pratsinis, H, Tsagarakis, S, Karavitaki, N, Stathakos, D, Thalassinos, N, Kletsas, D
Format:	Journal article
Idioma:	English
Publicat:	2005

Ítems similars

The Unexpected Anabolic Phenotype and Extended Longevity of Skin Fibroblasts after Chronic Glucocorticoid Excess
per: Harris Pratsinis, et al.
Publicat: (2006-04-01)

Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome.
per: Tzanela, M, et al.
Publicat: (2004)

Evaluation of bone mineral density of the peripheral skeleton in pre- and postmenopausal women with newly diagnosed endogenous Cushing's syndrome.
per: Karavitaki, N, et al.
Publicat: (2004)

Evaluation of GH reserve in patients with adrenal incidentalomas and biochemical evidence of subclinical autonomous glucocorticoid hypersecretion.
per: Tzanela, M, et al.
Publicat: (2005)

Coexistence of bone and vascular disturbances in patients with endogenous glucocorticoid excess
per: Chieko Yano, et al.
Publicat: (2022-12-01)

Metformin and Bone Metabolism in Endogenous Glucocorticoid Excess: An Exploratory Study
per: Frederick Vogel, et al.
Publicat: (2021-10-01)

E47 as a novel glucocorticoid-dependent gene mediating lipid metabolism in patients with endogenous glucocorticoid excess
per: Wei Zhang, et al.
Publicat: (2023-11-01)

Mortality in Cushing's syndrome: systematic analysis of a large series with prolonged follow-up.
per: Ntali, G, et al.
Publicat: (2013)

Challenges in the postsurgical recovery of cushing syndrome: glucocorticoid withdrawal syndrome
per: Catherine D. Zhang, et al.
Publicat: (2024-04-01)

Glucocorticoid-induced osteoporosis: lessons from Cushing's syndrome.
per: Tóth, M, et al.
Publicat: (2013)

Invasive fungal infections in endogenous Cushing’s syndrome
per: Rafael Selbach Scheffel, et al.
Publicat: (2010-06-01)

Etomidate in the management of hypercortisolaemia in Cushing's syndrome: a review.
per: Preda, V, et al.
Publicat: (2012)

Metabolic complications of endogenous Cushing: patient selection for screening
Publicat: (2013-03-01)

Activation of the JNKs/ATM-p53 axis is indispensable for the cytoprotection of dermal fibroblasts exposed to UVB radiation
per: Eleni Mavrogonatou, et al.
Publicat: (2022-07-01)

Cushing’s glucocorticoid syndrome in the practice of a rheumatologist (A review of literature)
per: Azamat Makhmudovich Satybaldyev
Publicat: (2013-12-01)

The Effect of Chronic Glucocorticoid Exposure on Brown Adipose Tissue in Cushing’s Disease
per: Alev Selek, et al.
Publicat: (2021-03-01)

Cushing’s syndrome with no clinical stigmata – a variant of glucocorticoid resistance syndrome
per: Ved V. Gossain, et al.
Publicat: (2018-12-01)

Disturbed bone marrow adiposity in patients with Cushing’s syndrome and glucocorticoid- and postmenopausal- induced osteoporosis
per: Nina N. Sørensen, et al.
Publicat: (2023-10-01)

The Regulation of Muscle Mass by Endogenous Glucocorticoids
per: Daniel L Marks, et al.
Publicat: (2015-02-01)

Co-Occurrence of Exogenous and Endogenous Cushing’s Syndromes—Dilemma in Diagnosis
per: Chin Voon Tong, et al.
Publicat: (2019-01-01)

Endogenous Obesity Associated with Cushing’s Disease: A Case Report
per: Müge Şahin, et al.
Publicat: (2021-03-01)

Role of endogenous glucocorticoids in hyperalgesia and edema in old arthritic rats
per: C.M. Yokoro, et al.
Publicat: (2003-01-01)

An N-ethyl-N-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess.
per: Bentley, L, et al.
Publicat: (2014)

An N-ethyl-n-nitrosourea induced corticotropin-releasing hormone promoter mutation provides a mouse model for endogenous glucocorticoid excess
per: Bentley, L, et al.
Publicat: (2014)

Modern Treatment of Cushing's Shows a High Cure Rate and a Low Mortality.
per: Ntali, G, et al.
Publicat: (2010)

Decreased Trabecular Bone Score in Patients With Active Endogenous Cushing’s Syndrome
per: Barbara Stachowska, et al.
Publicat: (2021-01-01)

Exogenous Cushing Syndrome: When do We Get the Benefit of Glucocorticoid Stress Dose?
per: Soebagijo Adi Soelistijo, et al.
Publicat: (2020-09-01)

The Impact of Environmental and Endogenous Damage on Somatic Mutation Load in Human Skin Fibroblasts.
per: Natalie Saini, et al.
Publicat: (2016-10-01)

Choroidal thickness and retinal abnormalities by optical coherence tomography in endogenous Cushing’s syndrome
per: Maria Fernanda Abalem, et al.
Publicat: (2016-12-01)

Adrenal Insufficiency under Standard Dosage of Glucocorticoid Replacement after Unilateral Adrenalectomy for Cushing’s Syndrome
per: Kentaro Fujii, et al.
Publicat: (2016-01-01)

The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing’s disease and silent corticotroph tumors
per: Paulina Kober, et al.
Publicat: (2023-03-01)

Clinical Characteristics of Endogenous Cushing’s Syndrome at a Medical Center in Southern Taiwan
per: Shih-Chen Tung, et al.
Publicat: (2013-01-01)

Endogenous glucocorticoids in inflammation: contributions of systemic and local responses
per: Rowan S. Hardy, et al.
Publicat: (2012-07-01)

Optogenetic elevation of endogenous glucocorticoid level in larval zebrafish
per: Rodrigo J De Marco, et al.
Publicat: (2013-05-01)

Neurocognitive functions and brain volume in patients with endogenous cushing's syndrome before and after curative surgery
per: Nachimuthu Kumar, et al.
Publicat: (2020-01-01)

AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome.
per: Christ-Crain, M, et al.
Publicat: (2008)

Design and Synthesis of Novel Antioxidant 2-Substituted-5,7,8-Trimethyl-1,4-Benzoxazine Hybrids: Effects on Young and Senescent Fibroblasts
per: Theano Fotopoulou, et al.
Publicat: (2024-06-01)

Therapy in endocrine disease: Etomidate in the management of hypercortisolaemia in Cushing's syndrome: A review (European Journal of Endocrinology 167, (137-143))
per: Preda, V, et al.
Publicat: (2013)

Different Potent Glucocorticoids, Different Routes of Exposure but the Same Result: Iatrogenic Cushing’s Syndrome and Adrenal Insufficiency
per: Ayla Güven
Publicat: (2020-12-01)

Holistic burden of illness in patients with endogenous Cushing's syndrome: A systematic literature review
per: Gabrielle Page‐Wilson, et al.
Publicat: (2024-01-01)